Dr Marc Moore

  1. 2022
  2. Forthcoming

    Targeted exon skipping of NF1 exon 17 as a Therapeutic for Neurofibromatosis Type I

    Leier, A., Moore, M., Liu, H., Daniel, M., Hyde, A. M., Messiaen, L., Korf, B. R., Selvakumaran, J., Ciszewski, L., Lambert, L., Foote, J., Wallace, M. R., Kesterson, R. A., Dickson, G., Popplewell, L. & Wallis, D., 15 Mar 2022, (Accepted/In press) In: Molecular therapy. Nucleic acids.

    Research output: Contribution to journalArticlepeer-review

  3. 2021
  4. Published

    Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C

    Awad, E., Moore, M., Liu, H., Ciszewski, L., Lambert, L., Korf, B. R., Popplewell, L., Kesterson, R. & Wallis, D., 7 Dec 2021, In: Journal of Personalized Medicine. 11, 12, 1320.

    Research output: Contribution to journalArticlepeer-review